Galapagos regains full rights to GPR84 inhibitor GLPG1205
16 12월 2014 - 3:32PM
Program to enter first Phase 2 patient study in
ulcerative colitis this month
Mechelen,
Belgium; 16 December 2014 - Galapagos NV (Euronext: GLPG) announced
today it has agreed with Janssen Pharmaceutica NV that Galapagos
will regain full and unencumbered rights to the entire GPR84
program going forward, which includes the inhibitor GLPG1205 and
its backup compound GLPG2196. No further details were
disclosed.
GLPG1205 ('1205), works on GPR84,
a novel mechanism of action developed by Galapagos for Inflammatory
Bowel Diseases (IBD). Earlier this year, Galapagos presented
compelling pre-clinical evidence for GPR84 playing a key role in
IBD pathology. The discovery of a selective antagonist of
GPR84 led to GLPG1205, which shows strong efficacy in relevant
pre-clinical models for IBD. Galapagos disclosed last year
that '1205 showed good safety, target engagement, and favorable
drug-like properties in Phase 1 studies in healthy
volunteers. Galapagos plans to initiate Phase 2 trial patient
recruitment before year end 2014.
About
GPR84
G-coupled protein receptor 84 (GPR84) is a free fatty acid protein
involved in the regulation of macrophages, monocytes, and
neutrophils in the human immune system. Galapagos identified
GPR84 as playing a key role in inflammation, using its proprietary
target discovery platform. GPR84 is over-expressed in
inflammatory disease patients. Galapagos has confirmed using
in vitro models that GPR84 inhibition prevents
neutrophil and macrophage chemotaxis induced by specific triggers,
and in relevant in vivo models that '1205
prevents IBD disease progression. Novel medicine '1205 is
also the first selective inhibitor of GPR84 to be tested in humans,
showing good safety, inhibition of GPR84, and favorable drug-like
properties in Phase 1 studies.
About
Galapagos
Galapagos (Euronext: GLPG; OTC:
GLPYY) is specialized in novel modes-of-action, with a large
pipeline comprising three Phase 2 studies, two Phase 1 studies,
five pre-clinical, and 20 discovery small-molecule and antibody
programs in cystic fibrosis, inflammation, antibiotics, metabolic
disease, and other indications. In the field of inflammation,
AbbVie and Galapagos signed an agreement for the development and
commercialization of GLPG0634. GLPG0634 is an
orally-available, selective inhibitor of JAK1 for the treatment of
rheumatoid arthritis and potentially other inflammatory diseases,
currently in Phase 2B studies in RA and in Phase 2 in Crohn's
disease. Galapagos has another selective JAK1 inhibitor,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program has
completed a Proof-of-Concept Phase 2 study. GLPG1205 is a
first-in-class molecule that targets inflammatory disorders and has
completed Phase 1. GLPG1690 is a first-in-class compound that
targets pulmonary diseases and is currently in a Phase 1
study. AbbVie and Galapagos signed an agreement in cystic
fibrosis to develop and commercialize molecules that address
mutations in the CFTR gene. Potentiator GLPG1837 is expected
to start Phase 1 this month. The first Galapagos corrector
GLPG2222 is at the pre-clinical candidate stage. The
Galapagos Group, including fee-for-service subsidiary Fidelta, has
around 400 employees, operating from its Mechelen, Belgium
headquarters and facilities in The Netherlands, France, and
Croatia. Further information at: www.glpg.com
CONTACT
Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications &
IR
Tel: +31 6 2291 6240
ir@glpg.com
Galapagos forward-looking
statements
This release may contain forward-looking
statements, including, without limitation, statements containing
the words "believes," "anticipates," "expects," "intends," "plans,"
"seeks," "estimates," "may," "will," "could," "stands to," and
"continues," as well as similar expressions. Such
forward-looking statements may involve known and unknown risks,
uncertainties and other factors which might cause the actual
results, financial condition, performance or achievements of
Galapagos, or industry results, to be materially different from any
historic or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking
statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of
the date of publication of this document. Galapagos expressly
disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Galapagos NV via Globenewswire
HUG#1880447
Galapagos (LSE:GLPG)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Galapagos (LSE:GLPG)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024